

PRICING & ORDERING GUIDE

For information regarding MYOBLOC®,
or to place an order, click or call toll-free:

1-888-461-2255

8:00 AM-8:00 PM, Eastern Time, Monday-Friday
Information • Ordering • Reimbursement



2,500 Units/0.5 mL
NDC# 10454-710-10*

\$317⁵⁴



5,000 Units/1 mL
NDC# 10454-711-10*

\$635⁰⁸



10,000 Units/2 mL
NDC# 10454-712-10*

\$1,270¹⁶

MYOBLOC IS:

- Delivered the next day if a phone order is received by 5:00 PM, Eastern Time[†]
- Packaged to maintain the required temperature between 36-46 °F (2-8 °C) during shipment. **MYOBLOC must be refrigerated**
- A ready-to-use liquid formulation that does not require reconstitution
- Do not freeze or shake



Visit
myoblochcp.com
for more information

*Please note that for billing purposes, some payers may require an 11-digit code based on the NDC number. Therefore, a zero must be entered into the sixth position (example: "10454-0710-10"). This is consistent with the Red Book and First Databank listings. Prices listed are updated as of May 22, 2023, and are subject to change without notice.

[†]Orders received on Friday are shipped the following Monday. MYOBLOC is not returnable for credit under any condition, including drug that has been mishandled or has expired. For assistance with disposal of expired drug, please contact Solstice Neurosciences, LLC at 1-888-461-2255 within 30 days of purchase. Payment terms for MYOBLOC are net 90 days. See Terms and Conditions for further details about ordering MYOBLOC by visiting myoblochcp.com and accessing the Ordering link.

INDICATIONS

MYOBLOC® injection is indicated for:

- the treatment of cervical dystonia (CD) to reduce the severity of abnormal head position and neck pain associated with CD in adults
- the treatment of chronic sialorrhea in adults

IMPORTANT SAFETY INFORMATION

WARNING: DISTANT SPREAD OF TOXIN EFFECT

See full prescribing information for complete boxed WARNING.

The effects of MYOBLOC® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults, particularly in those patients who have an underlying condition that would predispose them to these symptoms.

Please refer to the full [Prescribing Information](#) and additional Important Safety Information on [next page](#).

IMPORTANT SAFETY INFORMATION (cont'd)

CONTRAINDICATIONS

MYOBLOC is contraindicated in patients with:

- A known hypersensitivity to any botulinum toxin product or to any of the components in the formulation
- Infection at the proposed injection site(s)

WARNINGS AND PRECAUTIONS

▪ Lack of Interchangeability Between Botulinum Toxin Products

The potency units of MYOBLOC are specific to the preparation and biological activity assay method utilized. Due to differences in the aspects of this assay such as the vehicle, dilution scheme, and laboratory protocols for various potency assays, potency units are not interchangeable with other preparations of botulinum toxin products and, therefore, units of biological activity of MYOBLOC cannot be compared to or converted into units of any other botulinum toxin products assessed with any other specific assay method.

▪ Hypersensitivity Reactions

Serious hypersensitivity reactions have been reported with botulinum toxin products. Angioedema, urticaria, and rash have occurred with MYOBLOC treatment. Hypersensitivity reactions can also include anaphylaxis, serum sickness, soft tissue edema, and dyspnea. If serious and/or immediate hypersensitivity reactions occur, discontinue further injection of MYOBLOC and institute appropriate medical therapy immediately. The use of MYOBLOC in patients with a known hypersensitivity to any botulinum neurotoxin or to any of the excipients (human albumin, sucrose), could lead to a life-threatening allergic reaction.

▪ Dysphagia and Breathing Difficulties

Treatment with MYOBLOC and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. In most cases, this is a consequence of weakening of muscles in the area of injection that are involved in breathing or swallowing. When distant effects occur, additional respiratory muscles may be involved. Deaths as a complication of severe dysphagia have been reported after treatment with botulinum toxin. Dysphagia may persist for several months and require use of a feeding tube to maintain adequate nutrition and hydration. Aspiration may result from severe dysphagia and is a particular risk when treating patients in whom swallowing or respiratory function is already compromised.

– **Cervical Dystonia:** Treatment of cervical dystonia with botulinum toxins may weaken neck muscles that serve as accessory muscles of ventilation. This may result in a critical loss of breathing capacity in patients with respiratory disorders who may have become dependent upon these accessory muscles. There have been postmarketing reports of serious breathing difficulties, including respiratory failure, in cervical dystonia patients. Patients treated with botulinum toxin may require immediate medical attention should they develop problems with swallowing, speech or respiratory disorders. These reactions can occur within hours to weeks after injection with botulinum toxin.

– **Pre-Existing Neuromuscular Disorders:** Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) should be monitored particularly closely when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of MYOBLOC.

▪ Human Albumin and Transmission of Viral Diseases

This product contains albumin, a derivative of human blood. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), but if that risk actually exists, the risk of transmission would be considered extremely remote. No cases of transmission of viral diseases, CJD, or vCJD have ever been identified for licensed albumin or albumin contained in other licensed products.

MOST COMMON ADVERSE REACTIONS (>5% of patients and >5% more than placebo)

Cervical Dystonia: dry mouth, dysphagia, injection site pain, headache

Chronic Sialorrhea: dry mouth, dysphagia

DRUG INTERACTIONS

Aminoglycosides and Other Agents Interfering with Neuromuscular

Transmission: Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated. **Anticholinergic Drugs:** Use of anticholinergic drugs after administration of MYOBLOC may potentiate systemic anticholinergic effects.

Other Botulinum Neurotoxin Products: The effect of administering different botulinum toxin products at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin. **Muscle Relaxants:** Excessive weakness may also be exaggerated by administration of a muscle relaxant before or after administration of MYOBLOC.

Please see the full [Prescribing Information](#), including [Boxed WARNING](#).



MYOBLOC®
rimabotulinumtoxinB
Injection [5,000 Units/mL]



Supernus®
Pharmaceuticals

MYOBLOC is a registered trademark of Solstice Neurosciences, LLC,
a wholly-owned subsidiary of Supernus Pharmaceuticals, Inc.
© 2022. Supernus Pharmaceuticals, Inc. MYO.2022-0063 12/22.